PETSNasdaqRetail-Drug Stores and Proprietary StoresFiscal year ends March 31
PETMED EXPRESS INC
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.15−0.03 (-2.54%)
Close on Oct 19, 2026
- Market cap
- $24.93M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
28.1%+0.3 pts over 5 years
Operating margin
-32.8%−42.8 pts over 5 years
Net margin
-32.0%−39.9 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -21.1% | -10.2% | -10.0% | -2.7% | |
| Gross profit | -27.4% | -13.1% | -9.8% | -4.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 27.0% | 19.5% | -100.4% | |
| Return on assets | 23.5% | 14.0% | -49.8% | |
| Current ratio | 4.46 | 3.59 | 0.84 | |
| Inventory turnover | – | – | 8.6× | |
| Capex to revenue | 4.3% | 0.8% | 2.6% | |
| Diluted shares | 20M | 20M | 21M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Petmed Express generated $83.73M from operations and spent $82.81M on capital expenditure, dividends and share buybacks. 26% of that went back into the business.
Generated
$83.73M
Used
$82.81M
Capital expenditure$21.25M26%Dividends$61.56M74%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-32.0%
×Asset turnover1.56×
×Equity multiplier2.02×
=Return on equity, FY2026-100.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -32.0% | 1.56× | 2.02× | -100.4% |
| FY2025 | -2.8% | 1.42× | 1.75× | -6.9% |
| FY2024 | -2.7% | 1.62× | 1.63× | -7.2% |
| FY2023 | 2.1% | 1.43× | 1.49× | 4.4% |
| FY2022 | 6.9% | 1.48× | 1.48× | 15.1% |
| FY2021 | 7.9% | 1.77× | 1.40× | 19.5% |
| FY2020 | 9.1% | 1.83× | 1.21× | 20.3% |
| FY2019 | 13.3% | 1.96× | 1.16× | 30.1% |
| FY2018 | 13.6% | 2.21× | 1.18× | 35.7% |
| FY2017 | 9.6% | 2.45× | 1.15× | 27.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
1of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$57.29M
- Cash generatingOperating cash flow above zero-$28.39M
- Return on assets improvedROA up on the prior year-3.7% → -38.5%
- Earnings backed by cashOperating cash flow above net income-$28.39M vs -$57.29M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.26 → 0.84
- No dilutionShare count did not rise21M → 21M
- Gross margin improvedGross margin up on the prior year30.46% → 28.05%
- More efficientAsset turnover rose1.34 → 1.20